Establishment Labs to Participate in Two Upcoming Investor Conferences
31 May 2023 - 10:00PM
Business Wire
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global
medical technology company dedicated to improving women’s health
and wellness, principally in breast aesthetics and reconstruction,
today announced its participation in two upcoming investor
conferences.
Juan José Chacón-Quirós, Chief Executive Officer and Founder,
and Raj Denhoy, Chief Financial Officer, will participate in the
2023 Jefferies Healthcare Conference held June 7-9, 2023. Mr.
Chacón-Quirós and Mr. Denhoy are scheduled to speak in person to
conference attendees on Wednesday, June 7 at 9:00 AM ET.
Mr. Chacón-Quirós and Mr. Denhoy will also participate in the
Goldman Sachs 44th Annual Global Healthcare Conference held June
12-15, 2023, and are scheduled to speak in person to conference
attendees on Tuesday, June 13 at 11:40 AM PT.
Live webcasts of the presentations will be available to all
interested parties on the Establishment Labs investor relations
website at https://investors.establishmentlabs.com/. Archived
versions of the webcasts will be available on the same website
following completion of the events.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology
company dedicated to improving women’s health and wellness through
the power of science, engineering, and technology. The Company
offers a portfolio of Femtech solutions for breast health, breast
aesthetics and breast reconstruction. The over three million
Motiva® devices Establishment Labs has delivered to plastic and
reconstructive surgeons since 2010 have created a new standard for
safety and patient satisfaction in the over 85 countries in which
they are available. The Motiva Flora® tissue expander is the only
regulatory-approved expander in the world with an integrated port
that is MRI conditional and is used to improve outcomes in breast
reconstruction following breast cancer. Mia Femtech™, Establishment
Lab’s unique minimally invasive experience for breast harmony, is
the Company’s most recent breakthrough innovation. These solutions
are supported by over 200 patent applications in 25 separate patent
families worldwide and over 50 scientific studies and publications
in peer reviewed journals. Establishment Labs manufactures at two
facilities in Costa Rica compliant with all applicable regulatory
standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP
program. In 2018, the Company received an investigational device
exemption (IDE) from the FDA for Motiva Implants® and began a
clinical trial to support regulatory approval in the United States.
Please visit our website for additional information at
www.establishmentlabs.com.
Establishment Labs' implants and tools are currently not
approved for commercial distribution in the United States. The
Company’s Motiva implants are undergoing clinical investigation
pursuant to U.S. FDA regulations for investigational medical
devices.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230531005402/en/
Investor/Media Contact Raj Denhoy 415-828-1044
rdenhoy@establishmentlabs.com
Establishment Labs (NASDAQ:ESTA)
Historical Stock Chart
From Apr 2024 to May 2024
Establishment Labs (NASDAQ:ESTA)
Historical Stock Chart
From May 2023 to May 2024